Aggravation of spinal cord compromise following new osteoporotic vertebral compression fracture prevented by teriparatide in patients with surgical contraindications.

Zhao Y, Xue R, Shi N, Xue Y, Zong Y, Lin W, Pei B, Sun C, Fan R, Jiang Y

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA31 May 2016Cited by 22 (Europe PMC)

PMID27245056DOI10.1007/s00198-016-3651-2PepBankPUB-27245056

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In unstable vertebral compression fractures, mJOA scores improved with teriparatide but decreased with alendronate at 12 months.
In plain wordsIn unstable vertebral fractures, neurological scores improved with teriparatide but worsened with alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasemJOA neurological score
Study
n = 49
Comparator
Alendronate
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
At 12 months, mean mJOA score had improved in the teriparatide group and decreased in the alendronate group.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-month, randomized, open-label study of teriparatide versus alendronate in 49 patients with new unstable OVCF and surgical contraindications.
Report a problemFND-2724505601
02HumanRandomized controlled trialEfficacy outcome
In unstable vertebral compression fractures, bone formation biomarkers were higher with teriparatide than alendronate.
In plain wordsIn unstable vertebral fractures, bone formation markers were higher with teriparatide than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone formation biomarkers
Study
n = 49
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Mean concentrations of bone formation and bone resorption biomarkers, mean spine BMD, and mean anterior-border height and spinal canal diameter of the fractured vertebrae were significantly greater in the teriparatide group than in the alendronate group.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-month, randomized, open-label study of teriparatide versus alendronate in 49 patients with new unstable OVCF and surgical contraindications.
Report a problemFND-2724505602
03HumanRandomized controlled trialEfficacy outcome
In unstable vertebral compression fractures, bone resorption biomarkers were higher with teriparatide than alendronate.
In plain wordsIn unstable vertebral fractures, bone breakdown markers were higher with teriparatide than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone resorption biomarkers
Study
n = 49
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Mean concentrations of bone formation and bone resorption biomarkers, mean spine BMD, and mean anterior-border height and spinal canal diameter of the fractured vertebrae were significantly greater in the teriparatide group than in the alendronate group.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-month, randomized, open-label study of teriparatide versus alendronate in 49 patients with new unstable OVCF and surgical contraindications.
Report a problemFND-2724505603
04HumanRandomized controlled trialEfficacy outcome
In unstable vertebral compression fractures, spine BMD was higher with teriparatide than alendronate.
In plain wordsIn unstable vertebral fractures, spine bone density was higher with teriparatide than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine BMD
Study
n = 49
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Mean concentrations of bone formation and bone resorption biomarkers, mean spine BMD, and mean anterior-border height and spinal canal diameter of the fractured vertebrae were significantly greater in the teriparatide group than in the alendronate group.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-month, randomized, open-label study of teriparatide versus alendronate in 49 patients with new unstable OVCF and surgical contraindications.
Report a problemFND-2724505604
05HumanRandomized controlled trialEfficacy outcome
In unstable vertebral compression fractures, anterior-border height was greater with teriparatide than alendronate.
In plain wordsIn unstable vertebral fractures, vertebral front-edge height was greater with teriparatide than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseAnterior-border vertebral height
Study
n = 49
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Mean concentrations of bone formation and bone resorption biomarkers, mean spine BMD, and mean anterior-border height and spinal canal diameter of the fractured vertebrae were significantly greater in the teriparatide group than in the alendronate group.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-month, randomized, open-label study of teriparatide versus alendronate in 49 patients with new unstable OVCF and surgical contraindications.
Report a problemFND-2724505605
06HumanRandomized controlled trialEfficacy outcome
In unstable vertebral compression fractures, spinal canal diameter was greater with teriparatide than alendronate.
In plain wordsIn unstable vertebral fractures, the spinal canal was wider with teriparatide than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpinal canal diameter
Study
n = 49
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Mean concentrations of bone formation and bone resorption biomarkers, mean spine BMD, and mean anterior-border height and spinal canal diameter of the fractured vertebrae were significantly greater in the teriparatide group than in the alendronate group.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-month, randomized, open-label study of teriparatide versus alendronate in 49 patients with new unstable OVCF and surgical contraindications.
Report a problemFND-2724505606
07HumanRandomized controlled trialEfficacy outcome
In unstable vertebral compression fractures, VAS scores were lower with teriparatide than alendronate.
In plain wordsIn unstable vertebral fractures, visual analog scale scores were lower with teriparatide than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVAS score
Study
n = 49
Comparator
Alendronate
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Mean VAS score, mean kyphotic angle of the fractured vertebrae, and incidence of new OVCFs were significantly smaller in the teriparatide group than in the alendronate group.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-month, randomized, open-label study of teriparatide versus alendronate in 49 patients with new unstable OVCF and surgical contraindications.
Report a problemFND-2724505607
08HumanRandomized controlled trialEfficacy outcome
In unstable vertebral compression fractures, kyphotic angles were smaller with teriparatide than alendronate.
In plain wordsIn unstable vertebral fractures, spinal curvature angles were smaller with teriparatide than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseKyphotic angle
Study
n = 49
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Mean VAS score, mean kyphotic angle of the fractured vertebrae, and incidence of new OVCFs were significantly smaller in the teriparatide group than in the alendronate group.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-month, randomized, open-label study of teriparatide versus alendronate in 49 patients with new unstable OVCF and surgical contraindications.
Report a problemFND-2724505608
09HumanRandomized controlled trialEfficacy outcome
In unstable vertebral compression fractures, new fracture incidence was lower with teriparatide than alendronate.
In plain wordsIn unstable vertebral fractures, new fractures occurred less often with teriparatide than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNew vertebral compression fractures
Study
n = 49
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Mean VAS score, mean kyphotic angle of the fractured vertebrae, and incidence of new OVCFs were significantly smaller in the teriparatide group than in the alendronate group.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-month, randomized, open-label study of teriparatide versus alendronate in 49 patients with new unstable OVCF and surgical contraindications.
Report a problemFND-2724505609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Aggravation of spinal cord compromise following new osteoporotic vertebral compression fracture prevented by teriparatide in patients with surgical contraindications.

Summary

Results from this study9

Version history

Subjects

Publication types

MeSH terms

Keywords